[Insight] Celltrion Expands Omlyclo 300mg Across Europe, Turning First-Mover Lead Into Tender Advantage

Celltrion is expanding its 300mg version of the omalizumab biosimilar Omlyclo into key European markets. This move could help the company turn its early lead into a stronger position as competition emerges in the European omalizumab biosimilar market. The 300mg formulation of Omlyclo was first launched in Germany, the United Kingdom, and France.

This addition to the product portfolio includes pre-filled syringes and autoinjectors, which will cater to the varying needs of patients, healthcare professionals, and procurement institutions. With options for 75mg, 150mg, and 300mg, Omlyclo aims to address different patient requirements. The company plans to gradually roll out the 300mg formulation across Europe by the end of 2026.

The European Commission approved this higher-dose formulation in November 2025, following its approval of the 75mg and 150mg versions last year. The strategy behind this expansion is to leverage the early market entry advantage while addressing the growing competition in the European market. By providing more options, Celltrion aims to enhance the product's acceptance among patients, healthcare providers, and procurement institutions.

Omlyclo became the first omalizumab biosimilar approved by the European Commission in May 2024. The company began its European commercial rollout in 2025, gaining an early presence ahead of potential competitors. However, the market is now evolving. Another omalizumab biosimilar has been licensed in Europe, and other developers are advancing competing candidates through regulatory processes.

This shift in the market environment means that Celltrion's strategy is now focused on how effectively it can convert its early advantage into prescriptions, tender wins, and sustained market share. The 300mg rollout offers an additional tool in this strategy. The 300mg dosage can be administered in a single injection, reducing the injection burden on patients and simplifying treatment for healthcare providers.

Furthermore, the product is available in both pre-filled syringe and autoinjector formats, providing flexibility for healthcare professionals depending on the treatment setting and patient needs. The expanded product portfolio and competitive differentiation factors position Celltrion well for European tenders. The 300mg formulation adds to the company's regulatory strategy, which has been expanded to markets like the United States and Canada.

Celltrion's next step will be to measure the success of Omlyclo's European expansion through commercial execution. The company aims to pursue additional tenders in major European countries and utilize the secured volumes in the second half of the year. Establishing strong relationships with healthcare professionals, procurement institutions, and supply networks before new competitors gain ground will be crucial for Celltrion to preserve the benefits gained from its early entry.